Benufutamab Biosimilar - Research Grade

Human

TNFRSF10B

>1mg/ml

IgG1 - kappa

CHO Cells

Conatumumab Biosimilar - Research Grade (ICH5445), Drozitumab Biosimilar - Research Grade (ICH5491), Lexatumumab Biosimilar - Research Grade (ICH5640), Tigatuzumab Biosimilar - Research Grade (ICH5921), Tilogotamab Biosimilar - Research Grade (ICH5922)

https://www.imgt.org/mAb-DB/

ICH3002

O14763

Blue ice

This product is a research-grade biosimilar of benufutamab, supplied as an unconjugated, non-therapeutic analog of the originator molecule for research use only. It is not the clinical drug and is intended for laboratory investigation rather than any diagnostic or therapeutic application. The reagent is built around the target of the originator, death receptor 5 (DR5 / TNFRSF10B / TRAIL-R2, UniProt O14763), and is provided as a human IgG1, kappa antibody. It is worth noting that the originator benufutamab (GEN1029, also known by its HexaBody-DR5/DR5 designation) is not a single monoclonal but a defined mixture of two non-competing DR5-specific IgG1 antibodies carrying an E430G Fc mutation that promotes hexamerization; researchers comparing this single-format research analog to published originator data should keep that distinction in mind. Ichor supplies material at research-grade endotoxin levels (typically under 1 EU/mg) and in bulk milligram-to-gram quantities suitable for binding, functional, and control studies. As with all biosimilar analogs, this item is intended to support target-directed and comparative research rather than to reproduce the exact clinical formulation. DR5 (TNFRSF10B, also called TRAIL-R2, CD262, or KILLER) is a cell-surface death receptor in the TNF receptor superfamily and one of the two signaling receptors for the ligand TRAIL. On engagement and clustering, DR5 assembles a death-inducing signaling complex through its intracellular death domain, recruiting FADD and initiator caspase-8, which drives caspase-mediated apoptosis. DR5 is frequently expressed on tumor cells across many solid malignancies, making it an attractive oncology target: receptor clustering rather than simple occupancy is the key trigger for pro-apoptotic outside-in signaling. This clustering requirement is why agonistic DR5 antibody formats are engineered to enhance cross-linking, for example through Fc-Fc-driven hexamerization and dual-epitope binding, to achieve efficient, FcgammaR-independent receptor aggregation and tumor cell death.

Death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL receptor 2, TRAIL-R2, Tumor necrosis factor receptor superfamily member 10B, DR5, KILLER, TRICK2, ZTNFR9

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Benufutamab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Benufutamab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Benufutamab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Benufutamab that binds TNFRSF10B; for research use only.